Bausch Health Companies Inc (BHC) Stock Analysis
Verdict: WATCH (do not buy)
Operational momentum and $1B+ quarterly EBITDA fuel short-term rallies, but $20.8B net debt and negative equity limit long-term valuation.
Investment score: 52/100
Analysis as of
Is Bausch Health Companies Inc stock worth reviewing? The TradeMates thesis
Strong operational momentum with 14 consecutive growth quarters is counterbalanced by a $20.78B debt overhang and negative equity.
7-factor investment score
- Valuation: 45/100 (weight 20%)
- Financial Health: 30/100 (weight 15%)
- Technical Momentum: 82/100 (weight 15%)
- Earnings Quality: 70/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 48/100 (weight 10%)
- Risk-Adjusted Return: 40/100 (weight 15%)
Bausch Health Companies Inc opportunities and risks
What speaks for BHC
- Robust Core Franchise Cash Flow Generation
What speaks against BHC
- Loss of Patent Exclusivity on Key Revenues
Frequently asked questions about Bausch Health Companies Inc (BHC)
Is BHC stock a good investment?
The TradeMates model rates Bausch Health Companies Inc as WATCH (do not buy) with an investment score of 52/100. Strong operational momentum with 14 consecutive growth quarters is counterbalanced by a $20.78B debt overhang and negative equity. This is algorithmic model output, not personal investment advice.
Is BHC stock a buy?
The TradeMates model verdict for BHC is WATCH (do not buy) with an investment score of 52/100. Treat this as a model signal to review, not a personal buy recommendation.